The purpose of this study was to determine whether a single intramuscular injection of dexamethasone decreased the duration of symptoms of acute bronchiolitis in young children.

Condition	Intervention
Bronchiolitis, Viral	Drug: dexamethasone

Further Study Details: 

Primary Outcomes: The time from study entry to respiratory distress resolved, which was defined as the following: respiratory rate score of 0 or 1; wheezing score of 0 or 1; retraction muscle score of 0 or 1; and oxygen saturation greater than or equal to 95% without oxygen
Secondary Outcomes: The duration of oxygen therapy; The length of hospital stay; Additional drugs used; Emergency visit and hospital readmission within one month after discharge; Adverse drug events
Expected Total Enrollment:  170

Acute bronchiolitis is an infection of the lower respiratory tract causing inflammation of the small airways, leading to bronchiolar obstruction. Corticosteroids are frequently prescribed as anti-inflammatory drugs. The usefulness of corticosteroids for this disease remains controversial, despite many randomized controlled trials (RCTs). Recently, a meta-analysis and systemic review showed significant improvement in clinical symptoms, length of hospital stay and duration of symptoms in children with this disease after treatment with various regimens of systemic corticosteroids.

Dexamethasone is a long acting corticosteroid with biologic half-life ranging from 36-72 hours. A single dose of dexamethasone has been the standard recommendation for the treatment of croup which has a similar pathophysiology without evidence of adverse effects. Furthermore, there is no previous report of this single dosage form of dexamethasone for the treatment of acute bronchiolitis in young children.

Ages Eligible for Study:  up to  24 Months,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Aged 4 weeks - 24 months
• Has the first episode of wheezing within 7 days
• Has evidence of viral infection
• Requires hospital admission; criteria for admission include one of the following: age < 3 months; respiratory rate > 60 breaths/minute for age < 12 months or 50 breaths/minute for > or equal to 12 months; oxygen saturation in room air < 95% and apathy or refuses feeding.

Exclusion Criteria:

• Initial admission to intensive care unit
• Initial requirement for endotracheal intubation or mechanical ventilation
• A previous history of intubation
• A known history of asthma or response to the first dose of beta2 agonist nebulization
• A history of prematurity
• A history of bronchopulmonary dysplasia or chronic lung disease
• Underlying congenital heart disease or immunodeficiency
• Receives treatment of any form of corticosteroids within 2 weeks
• Has contraindication to corticosteroid treatment

Thailand
      Srinagarind Hospital, Khon Kaen University and Khon Kaen Hospital, Ministry of Public Health, Khon Kaen,  40002,  Thailand

Study chairs or principal investigators

Jamaree Teeratakulpisarn, M.D.,  Principal Investigator,  Faculty of Medicine, Khon Kaen University, Thailand   

Study ID Numbers:  HE44243
Last Updated:  August 1, 2005
Record first received:  July 21, 2005
ClinicalTrials.gov Identifier:  NCT00122785
Health Authority: Thailand: Khon Kaen University Ethics Committee for Human Research
ClinicalTrials.gov processed this record on 2005-08-02